Intravenous nutrition has been a major advance in neonatal intensive care. The clinical safety of intravenous feeding solutions, however, has been subject to continued vigilance. Over the past five years there has been a number of reports of increased plasma phenylalanine concentrations in infants fed certain intravenous amino acid solutions, notably Vamin 9 (Kabi), which has been much used in Britain for term and preterm neonates. [1] [2] [3] [4] [5] As increased plasma phenylalanine in phenylketonuria is well known to be associated with long term neurological damage6 it has been argued, by analogy, that hyperphenylalaninaemia in intravenously fed infants could damage the developing brain.
We have studied plasma phenylalanine concentrations in the early weeks after birth in 336 intensively monitored preterm infants, survivors of whom have had neurodevelopmental assessments at 18 months post-term. These data have been used to derive reference concentrations for plasma phenylalanine, to quantify the prevalence and severity of hyperphenylalaninaemia in infants fed intravenously with Vamin 9, to explore the relation of increased plasma phenylalanine with later developmental scores, and to examine whether attention to the design of intravenous feeding regimens, notably the total energy to protein energy (TE:PE) ratio, could minimise disturbances in plasma concentrations of this amino acid.
Subjects and methods A total of 336 preterm infants weighing less than 1859 g at birth were studied in five centres (Cambridge, Ipswich, Kings Lynn, Norwich, and Sheffield). The infants were taking part in a larger long term randomised outcome study on the effects of early diet. 7 8 Venous blood specimens were obtained for amino acid analyses in the morning at the time of clinically indicated sampling. Specimens were collected in cooled tubes and the plasma was separated and placed in -20°C storage within 30 minutes. Samples were obtained weekly until the infant was discharged or attained a body weight of 2000 g, whichever was the sooner. All plasma samples were stored at -20°C until analysed.
After thawing at room temperature samples were gently vortexed before the aliquots for analysis were removed. A volume of 1 0 ,lI was then withdrawn and transferred to a round bottomed polystyrene tube, together with 92
[lI 0-2 M lithium citrate loading buffer (pH 2 2) containing the norleucine internal standard (250 nmol/ml) and the sulphosalicylic acid deproteiniser (2) (3) (4) (5) mg/100 [lI of 0-2 M lithium citrate. The sample was vortexed and allowed to stand at 4°C for one hour after which it was centrifuged at 2500 rpm for 15 minutes, also at 4°C. The supematant was decanted into a microfilter system (Anachem Ltd, Cat No BAS MF5500) using a 0-2 ,um regenerated cellulose membrane filter, and centrifuged again for 15 minutes at 2500 rpm (4°C). A final sample volume of 100 pI filtrate was analysed in an LKB Alpha Plus 4151 analyser using a physiological fluids programme with the lithium citrate buffer ninhydrin system. The results were processed by an in line Hewlett-Packard 3392A integrator.
Of the 336 infants studied, 243 never received intravenous amino acids. The 93 infants requiring an intravenous amino acid solution were given Vamin 9. Table 1 gives demographic and clinical data collected for these two groups of infants.
The detailed clinical and demographic information collected allowed calculation of the TE:PE ratio of nutrients consumed by the intravenous and enteral routes during the course of intravenous nutrition. These data were used to relate the TE:PE ratio to the peak plasma phenylalanine concentration.
At 18 months post-term surviving infants were invited for follow up which included application of the Bayley scales for mental and psychomotor development.9 Language, fine motor and cognitive subscales were also calculated from the Bayley mental development scale.'0 The questionnaire based Vineland social maturity scales" were administered to the care giver and a social quotient was derived from the equation: (social age)/(age from expected date of delivery) X 100.
This follow up was conducted on 278 infants, representing a 95% follow up rate of survivors.
Statistical analyses included the x2 test, Student's t test, and multiple regression analysis to examine the relation between peak plasma phenylalanine concentration and developmental outcome after adjusting for potentially confounding factors. Table 1 shows, as expected, that infants who received Vamin had a lower mean birth weight and gestational age and required more ventilation than those who did not require intravenous amino acids. Those receiving Vamin were given it for a median of 10 days (table 1) .
Results
Reference centile data were compiled for plasma phenylalanine in the 243 infants who did not receive intravenous amino acids. Exploratory analysis showed no significant difference between values in the gestational age groups 25-28 weeks, 29-32 weeks, and 33-36 weeks. These three groups were therefore combined (see table 2 ). There was a slight decrease in the values over the first two weeks which then stabilised and values remained constant during the period of study (up to 2000 g body weight).
When the maximum (peak) plasma phenylalanine concentration was taken for each infant in this group the 95th centile was 102 pumol/l (table 3) . Only three values were above 150 (99th centile), and the highest of these was 202 pRmol/l. table 3 ). The 95% centile for this group was 415 p.mol/l, over four times that for the 95% centile value in the reference population. The highest value recorded was 704 ,umol/l (table 3) .
We investigated whether the higher values in the group fed with Vamin could be explained by the fact that this group tended to contain the smaller, sicker infants. Seventeen infants who did not receive intravenous amino acids, however, had respiratory disease requiring ventilation for one week or more and 23% weighed less than 1200 g at birth (used to define the high risk low birthweight stratum in our multicentre study), yet none of these infants had peak plasma phenylalanine concentrations greater than 202 ,umol/l and most had concentrations less than 100 ,umol/l. Regression analysis was also used to adjust the difference in plasma phenylalanine concentrations between the Vamin and non-Vamin fed groups for potential confounders, including birth weight, gestation, and days of ventilation. The adjusted difference between groups was little different to that seen in the raw data and was equally significant. Finally, in all instances when a Vamin fed infant developed a plasma phenylalanine concentration greater than 200 ,umol/l (above the reference range), this only occurred while the Vamin was being infused.
The relation of TE:PE ratio with peak plasma phenylalanine concentration was explored in 42 infants who received more than 1 g of intravenous protein each day for the 72 hours before the time of their peak plasma phenylalanine concentration. Table 4 shows that infants with peak plasma phenylalanine concentrations less than 100 ,umol/l had the highest TE:PE ratios and those with peak indices, subscales of mental development, or with the social maturity quotient. A further entrations greater analysis showed no relation between developvest TE:PE ratios. mental outcome and duration of hyperphenyln each group; the alaninaemia (weeks of recorded value greater the group with the than 100, 150, or 200 ,umol/l). As an example 4). These protein of this lack of a relation, table 5 shows data for lude the relatively the models relating peak plasma phenylt enteral feed con-alanine, as a continuous variable, to developts. Our data could mental scores. Of the 66 infants followed up at atios reduced the 18 months who received Vamin, five (8%) henylalanine con-had maximum phenylalanine concentrations ,that this relation greater than 300 ,umol/l, a value above which e infants with the developmental scores have been shown to be ilanine concentra-progressively affected in phenylketonuria.6 he lowest protein When these five infants, whose peak plasma ssion analysis was phenylalanine concentration was in the range ratio to the peak 327-539 ,umol/l, were compared with the entration (depen-remaining infants who received Vamin, the sting for protein mean mental development index (unadjusted) E ratio remained was the same at 91-4 (SE 10-1) v 92-5 (3 0), ak plasma phenyl-respectively; motor scores were higher, though protein intake not significantly, in the group with high 0-3-6 g/day) had phenylalanine concentrations (96&6 (8&4) v h plasma phenyl-88-0 (2-3)).
Discussion
This study confirms that infants fed intravenously with the amino acid solution Vamin 9 often have increased plasma phenylalanine concentrations compared with the reference values we and others'2 have derived. These high values may be the result of the low TE:PE ratios often used at the time when the infants were undergoing neonatal intensive care . Nevertheless, even when infants had increased plasma phenylalanine concentrations, these could not be shown to relate to impaired mental development, motor development, or social maturity at a corrected age of achievable.6 Of the infants who received Vamin 9 who we followed up at 18 months about 8% had sustained values above this (highest 539 ji.mol/l); it has been suggested, by analogy with phenylketonuria, that the high concentrations of phenylalanine in Vamin 9 might result in neurological damage, perhaps especially in the preterm infant who is undergoing extremely rapid brain growth.5 In phenylketonuria, however, increased plasma phenylalanine concentrations occur in isolation, competing with other neutral amino acids for the carrier mechanism across the blood-brain barrier such that the cerebral uptake of phenylalanine is likely to be greatly increased and the uptake of a number of other amino acids considerably decreased (for instance, that of methionine, histidine, isoleucine, tryptophan, threonine, and tyrosine). 13 figure) indicate that the chance of increased phenylalanine concentrations is minimised when the TE:PE ratio is greater than 8-5:1, which corresponds to a suggested minimum energy intake of 34 kcal (142 kJ)/g protein.
This guideline value of 8-5:1 for the ratio of TE:PE corresponds to a protein energy intake approaching 12% of the total dietary energy. When the infants were placed on enteral feeds they received one or more of the following: human milk providing only 6% of the total energy as protein, a standard 'term' formula providing 8 /5%, or a preterm formula providing 10% of energy as protein and designed to meet the high protein needs of the preterm infant. Most of the intravenously fed infants in this study, however, had protein energy intakes substantially in excess of this. It is, perhaps, not surprising that hyperphenylalaninaemia occurred in all the infants studied when the percentage of protein energy exceeded 15% (TE:PE 6-5:1). Furthermore, one of seven infants shown in the figure had a protein energy intake in excess of 20% of the total energy intake. These calculations emphasise that it is possible to devise intravenous feeding regimens which can, and often do, provide grossly unphysiological protein energy ratios that would not be encountered with normal foods.
New amino acid solutions designed specifically for use in infancy have now been introduced. Each new solution is based on an assumed 'ideal' biological model; for instance, the breast fed infant, the fetus, or the breast milk fed preterm infant.'6 17 The superiority of any of these biological models has yet to be shown by conclusive outcome trial. Nevertheless, the data of McIntosh and Mitchell5 using one of these new solutions (MB233G, Cernap Synthelabo) and our own (unpublished) data on another (Vamin Infant, Kabi) show that plasma phenylalanine concentrations in intravenously fed newborn infants can be reduced compared with those seen with Vamin 9. Our data suggest that attention to the TE:PE ratio in intravenous feeding regimens could result in a substantially reduced risk of hyperphenylalaninaemia. For infants who sustained high plasma concentrations of phenylalanine while receiving Vamin 9, however, our developmental data at this stage in our follow up programme, reassuringly, do not provide any evidence of impaired outcome.
